Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

2(40.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(2)

Phase 3(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT05581121Phase 3Recruiting

PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

Role: collaborator

NCT02730429Phase 2Completed

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Role: collaborator

NCT03267589Phase 2Completed

Trial in Patients With Relapsed Ovarian Cancer

Role: collaborator

NCT01658930Not ApplicableCompleted

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

Role: collaborator

NCT02354131Phase 1Completed

Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer

Role: collaborator

All 5 trials loaded